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(57) ABSTRACT 
The invention provides a method of up-regulating genes in 
cultured human bone marrow mesenchymal stem cells, the 
method comprising culturing the stem cells in a nutrient 
medium together with cells from a limb of a limb-regenerat-
ing animal. In the method, the limb-regenerating animal is 
preferably a species of the family Polychrotidae. Another 
method of the invention provides for up-regulating genes 
maintaining pluripotency and proliferation in cultured human 
bone marrow mesenchymal stem cells by culturing the stem 
cells in a nutrient medium together with mouse embryonic 
stem cells. 
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METHODS FOR MODIFYING STEM CELL 
CHARACTERISTICS 
RELATED APPLICATION 
This application claims priority from provisional applica-
tion Ser. No. 60/950,672 which was filed on 19 Jul. 2007 and 
which is incorporated herein by reference in its entirety. 
2 
up to about 150 cells. ESCs can differentiate into any cell type 
in the adult body, of which there are over two hundred types. 
Obviously, such differentiation would require the proper 
nutrition and growth conditions, as well as the correct stimuli 
for development. 
To date, just about all research has been based on mouse 
embryonic stem cells (mESCs) and on human embryonic 
stem cells (hESCs ). These two cells types have the required 
characteristics of stem cells but demand quite different cul-
FIELD OF THE INVENTION 
This invention relates to cellular differentiation and, more 
specifically, to methods of modifying the developmental 
potential of a cell and, particularly, of stem cells. 
10 ture conditions and environment, without which they will 
quickly differentiate, losing their stem cell potential. Human 
ESCs are further defined by the presence of certain cell mark-
ers, including transcription factors and cell surface proteins. 
These include Oct-4, NANOG, and Sox2, all transcription 
BACKGROUND OF THE INVENTION 
15 factors which help suppress genes that, if active, would lead to 
differentiation. Also, SSEA3 and SSEA4 cell surface gly-
colipids as well as Tra-1-60 and Tra-1-81 surface antigens. 
Other markers which may help identify a stem cell are being Every multicellular organism contains stem cells that have 
the ability to differentiate into any other cell in the body. 
Because stem cells are essentially precursors of many other 20 
cell types, there has been much research interest in elucidat-
ing their cellular mechanisms. Imagine the promise of being 
able to culture replacement tissues or even whole organs from 
stem cells. Additionally, the potential for using stem cells to 
repair damaged tissues may be applicable to a wide range of 25 
disease conditions. 
Mammalian stem cells typically originate from three 
sources. Embryonic stem cells are obtained from early 
embryos, particularly the blastocyst stage of embryonic 
development. Adult stem cells are those which are found in 30 
adult tissues, which generally contain at least a small comple-
ment of these primordial cells that can further develop into the 
specialized cells of the particular tissue and thereby provide a 
repair function. Lastly, cord blood stem cells are obtained 
from umbilical cord blood obtained around the time of birth. 35 
Embryonic stem cells, in particular, are at the center of a 
politico-religious controversy focused on the need for 
destroying a fertile human embryo when harvesting the stem 
cells. This debate has caused the federal government, at least 
to date, to deny research funding for projects involving 40 
embryonic stem cells. 
A stem cell is characterized by the ability to renew itself, 
that is, it maintains its undifferentiated state while undergoing 
many cycles of cell division; it proliferates, yet it remains a 
progenitor cell. Secondly, to be considered a stem cell, it must 45 
retain the ability to morph into any other cell type. The term 
"stem cell" is sometimes also applied to progenitor cells that 
have the ability to form only a specific type of mature cell. 
Stem cells are described by the scope of their potency, that 
is, by the range of mature cells which the stem cell can 50 
differentiate into. Totipotent stem cells possess the broadest 
developmental ability and can form any other downstream 
cells. Totipotent stem cells are formed very early in the 
embryonic cycle, for example, from a fertilized egg and its 
first few divisions. Pluripotent stem cells develop from toti- 55 
potent cells and have the ability to form cells of any of the 
three germ layers in the body: ectoderm, endoderm and meso-
derm. 
In vitro culture of stem cells may cause a change in the 
biochemistry of the cells and may result in stem cells which 60 
do not behave as they might be expected to in vivo. Accord-
ingly, there is disagreement in the scientific community as to 
whether some presently maintained cell lines are truly to be 
considered stem cells. 
studied as well. 
An "adult stem cell" is one which is found in the fully 
developed organism but which yet retains its ability to divide 
to form others like itself and also retains the ability to differ-
entiate into more specialized cells. These cells are also known 
as somatic stem cells and are found not only in adults but also 
in children. Somatic stem cells are typically restricted in their 
differential capacity so that they are able to form a limited 
range of more specialized cells. Accordingly, they are often 
named by their tissue of origin, for example, mesenchymal 
stem cells, endothelial stem cells, and others. 
Much research has been devoted to environmental factors 
that influence the differentiation of stem cells or even the 
regression of differentiated cells back to undifferentiated 
stem cells. In fact, there have been very recently two reports 
describing the generation of stem cells from fully differenti-
ated skin cells. The potential is there for regressing fully 
differentiated cells into stem cells which can then be differ-
entiated into yet other types of specialized cells. This is of 
great interest, as it would completely render moot the argu-
ment over destruction of a human embryo in order to obtain 
hESCs. 
When stem cells divide, they may form two stem cell 
daughter cells (symmetric division), or may form one stem 
cell and one daughter cell having less potential (asymmetric 
division). How this process is determined is unknown at this 
time. One school of thought holds that the specific segrega-
tion of cell membrane proteins may determine asymmetric 
division. In our view, this uneven segregation of cell mem-
brane proteins is more likely a symptom of asymmetric divi-
sion, ratherthan a cause ofit.Another school of thought holds 
that environmental factors influence stem cells to remain 
undifferentiated. If these environmental factors change in 
some way, then the stem cells will differentiate. 
SUMMARY OF THE INVENTION 
With the foregoing in mind, the present invention advan-
tageously provides methods of maintaining the pluripotency 
of cultured human bone marrow mesenchymal stem cells by 
providing environmental factors that influence their state. 
A method of the invention provides for up-regulating genes 
that maintain the pluripotency and proliferation of cultured 
human bone marrow mesenchymal stem cells by culturing the 
stem cells in a nutrient medium together with cells from a 
limb of a limb-regenerating animal. The inventors theorize, 
The earliest type of stem cell, embryonic stem cells 
(ESCs ), originate in the blastocyst stage of an embryo, which 
in the human would be about four or five days old and contain 
65 while not wishing to be bound by this particular explanation 
of the invention, that limb cells from a limb-regenerating 
animal possess factors which, when present in the culture 
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medium, will influence human bone marrow mesenchymal 
stem cells to proliferate and to maintain their pluripotency. 
These pluripotency maintenance factors (PMF) may be poly-
nucleotides, polypeptides, or others. Nevertheless, when in 
co-culture with limb-regenerating cells, the human stem cells 
demonstrate up-regulation of several genes involved in pluri-
potency and proliferation. In the method, the limb-regenerat-
ing animal is preferably a species of the family Polychrotidae 
and, particularly, the typical garden lizard species found in 
Florida. It should be understood that PMF may be provided in 
the stem cell culture medium whether or not the PMF-pro-
ducing cells themselves are in co-culture with the stem cells. 
The invention additionally provides a method of up-regu-
lating genes maintaining pluripotency and proliferation in 
cultured human bone marrow mesenchymal stem cells, the 
method comprising culturing the stem cells in a nutrient 
medium together with mouse embryonic stem cells. As 
above, the proposed mechanism of action involves the mouse 
embryonic stem cells producing various cellular factors 
which are then present in the culture medium and which 
influence the metabolism of the human stem cells by up-
regulating a number of genes. As noted above, the PMF may 
be provided in a cell-free culture medium for stem cells. 
BRIEF DESCRIPTION OF THE DRAWINGS 
Some of the features, advantages, and benefits of the 
present invention having been stated, others will become 
apparent as the description proceeds when taken in conjunc-
tion with the accompanying drawings, presented for solely 
for exemplary purposes and not with intent to limit the inven-
tion thereto, and in which: 
FIG. 1 comprises FIGS. lA, lB and lC and shows in lA 
control human mesenchymal stem cells (hMSCs ), in lB and 
lC views of hMSCs co-cultured with lizard tail extract 
according to an embodiment of the present invention; and 
FIG. 2 is a fluorescence microscopy view ofhMSCs treated 
with mito-red and co-cultured with mESC-YFP for 48 hours; 
immunostaining where red portions are human nucleoli and 
green portions are NANOG. 
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENT 
The present invention will now be described more fully 
hereinafter with reference to the accompanying drawings, in 
which preferred embodiments of the invention are shown. 
Unless otherwise defined, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which this invention 
pertains. Although methods and materials similar or equiva-
lent to those described herein can be used in the practice or 
testing of the present invention, suitable methods and mate-
rials are described below. Any publications, patent applica-
tions, patents, or other references mentioned herein are incor-
porated by reference in their entirety. In case of conflict, the 
present specification, including any definitions, will control. 
In addition, the materials, methods and examples given are 
illustrative in nature only and not intended to be limiting. 
Accordingly, this invention may be embodied in many differ-
ent forms and should not be construed as limited to the illus-
trated embodiments set forth herein. Rather, these illustrated 
embodiments are provided so that this disclosure will be 
thorough and complete, and will fully convey the scope of the 
invention to those skilled in the art. Other features and advan-
tages of the invention will be apparent from the following 
detailed description, and from the claims. 
4 
Modifying Stem Cell Characteristics Using Cell Extracts 
Cellular dedifferentiation aims to modify the developmen-
tal potential ofa cell. Our previous research has demonstrated 
the ability to modify the developmental potential of a cell by 
treatment with nucleotide derivatives or chromatin modifying 
compounds. Following treatment of human bone marrow 
mesenchymal stem cells with these drugs, there was an up-
regulation of stem cell markers. Additionally, we have also 
demonstrated that forced expression of stem cell genes up-
10 regulated the expression of other genes responsible in self-
renewal and pluripotency. We demonstrated that when these 
genes are up-regulated, cells are able to develop beyond their 
normal cell fates. For example, human mesenchymal stem 
cells can develop into neurons (including dopaminergic neu-
15 rans), glial, inner ear hair cells, etc. 
The present disclosure demonstrates an additional method 
for modifying the developmental potential of cells using 
extracts of other cells. Specifically, we have shown that cul-
turing stem cells in a nutrient medium containing cell prod-
20 ucts from a lower species, the tail of an animal capable oflimb 
regeneration (for example, the common garden lizards found 
in Florida, commonly known as Anoles and, in general, the 
family Polychrotidae) up-regulates genes associated with 
pluripotency (such as Oct4 and Sox2) as well as increasing 
25 proliferation (TERT, and TERP). Genes highlighted in green 
show up-regulation of stem cell genes relative to controls 
using real-time PCR. Morphological analysis of cells in cul-
ture reveals phenotypic alterations comparable to more primi-
tive (embryonic-like) stem cells rather than the cells' more 
30 typical spindle-shaped morphology. Table 1 summarizes the 
results of co-culturing mesenchymal stem cells with lizard 
tail sections and shows up-regulation of at least three genes 
associated with maintaining the potency of the stem cells: 
Oct4, Sox2, TERT and TERP. FIG. 1 illustrates aspects of 
35 Table 1. 
We then also examined if exposure to less differentiated 
cells, for example, mouse embryonic stem cells, could alter 
the cell fate of the host cells. Culturing human mesenchymal 
stem cells in direct contact with cells of another lower species, 
40 specifically, mouse embryonic stem cells, reveals dramatic 
up-regulation of stem cell genes (highlighted in green) as well 
as morphological changes. Fluorescent microscopy reveals 
that mitochondrial-labeled human mesenchymal stem cells 
show expression of NANOG following co-culture. Taken 
45 together, we believe these data demonstrate that cellular 
extracts can act on a human cell and modify and/or expand its 
developmental potential through the up-regulation of stem 
cell genes. Table 2 summarizes the results of co-culturing 
mesenchymal stem cells with mouse embryonic stem cells 
50 and shows up-regulation of multiple genes associated with 
maintaining the potency of the stem cells: Lefty, Oct4, 
DNMT3L, Zfp, HRPT, Activin RIIa, Sox2, FoxD3, NANOG, 
TERT, TERP and Eras. FIG. 2 illustrates aspects of Table 2. 
An extract from the embryonic stem cells or regenerative 
55 limb would be protein extracts. Protein extracts can be col-
lected through ultra-centrifugation or other protein purifica-
tion techniques. The co-culture with mouse embryonic stem 
cells was employed to assure that changes demonstrated in 
the human bone marrow mesenchymal stem cell culture were 
60 truly changes in the human stem cells (this was checked using 
human specific primers) rather than contamination from the 
mouse stem cell cultures. 
Potential applications of the present invention include new 
cell culture media formulations containing cell products that 
65 induce modifications in stem cells. Also, the invention shows 
the potential use of cell product extracts to improve regenera-
tion and cellular repair, improving stem cell transplants (in-
US 8,105,832 Bl 
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eluding those derived from nuclear transfer) by treating cells 
with concentrated extracts or placing the extracts within a cell 
cytoplasm. 
Accordingly, in the drawings and specification there have 
been disclosed typical preferred embodiments of the inven-
tion and although specific terms may have been employed, the 
terms are used in a descriptive sense only and not for purposes 
of limitation. The invention has been described in consider-
able detail with specific reference to these illustrated embodi-
ments. It will be apparent, however, that various modifica- 10 
tions and changes can be made within the spirit and scope of 
the invention as described in the foregoing specification and 
as defined in the appended claims. 
TABLE 1 
6 
culturing the human bone marrow mesenchymal stem cells 
in a nutrient medium together with cells from a tail of a 
tail-regenerating lizard; 
wherein the up-regulated genes comprise genes respon-
sible for maintaining pluripotency of the stem cells or 
genes responsible for cell proliferation; or both; 
wherein the genes responsible for maintaining pluripo-
tency of the stem cells are selected from the group con-
sisting of Oct4, Sox2, and combinations thereof; and 
wherein the genes responsible for cell proliferation are 
selected from the group consisting ofTERT, TERP, and 
combinations thereof. 
Co-culture with tail sections shows up-regulation of embryonic stem cell markers in human bone marrow stem cells. 
61120 cDNA Control MSC Tail co-culture, mESC-YFP co-culture, 2m Nanog transfection 
GAPDH 
Lefty 
Connexin 
Oct4 
DPPA5 
DNMT3L 
Zfp 
HPRTl 
bActin 
BMPRla 
Activin RI!a 
Sox2 
FoxD3 
Nanog 
TERT 
TERF 
Eras 
MSC Tail co-culture 
Tail co- CtCont-
Control culture CtHathl Pfaffi eq 
40 19.77 20.231229807 
30.56 25.82 4.74 26.72281 
28.35 26.95 1.4 2.639016 
33.82 25.15 8.67 407.3147 
40 36.82 3.18 9.063071 
40 37.58 2.42 5.35171 
34.61 34.38 0.23 1.172835 
40 40 0 
24.11 18.68 5.43 43.11147 
30.49 29.91 0.58 1.494849 
30.01 32.57 -2.56 0.169576 
40 29.03 10.97 2005.853 
36.96 40 -3.04 0.121582 
23.89 23.88 0.01 1.006956 
37.78 28.63 9.15 568.0996 
40 27.69 12.31 5077.843 
28.94 27.02 1.92 3.784231 
CtCon-CtTail-hMSC co-
culture 
5.43 
5.43 
5.43 
5.43 
5.43 
5.43 
5.43 
5.43 
5.43 
5.43 
5.43 
5.43 
5.43 
5.43 
5.43 
5.43 
5.43 
TABLE2 
Beta 
Ac tin 
Ratio of target 
genes 
43.11147 28526.2 
43.11147 
43.11147 
43.11147 
43.11147 
43.11147 
43.11147 
43.11147 
43.11147 
43.11147 
43.11147 
43.11147 
43.11147 
43.11147 
43.11147 
43.11147 
43.11147 
0.619854 
0.061214 
9.447941 
0.210224 
0.124137 
0.027205 
0.023196 
0.034674 
0.003933 
46.52712 
0.0282 
0.023357 
13.17746 
117.784 
0.087778 
Co-culture with mouse embryonic stem cells shows up-regulation of embryonic stem cell markers in hwnan 
bone marrow stem cells. 
61204hMSC mESC-YFP direct co-culture lw and controls p3 MSC 
mESC co- CtCont- CtCon-CthMSC co- Ratio of target 
Control culture CtHathl Pfaffi eq. culture Beta Actin genes 
Lefty 
Connexin 
Oct4 
DPPA5 
DNMT3L 
Zfp 
HRPT 
bActin 
BMPRla 
Activin RI!a 
Sox2 
FoxD3 
Nanog 
TERT 
TERF 
Eras 
32.41 
22.88 
29.53 
35.43 
37.76 
32.95 
26.75 
18.68 
25.41 
34.61 
37.88 
32.31 
28.79 
35.37 
26.31 
18.22 
32.15 
42.95 
31.34 
41.59 
36.94 
35.9 
29.51 
24.42 
39.72 
35.47 
25.88 
32.64 
30.84 
28.65 
29.98 
30.84 
That which is claimed: 
0.26 1.197479 -5.74 
-20.07 9 .09E-07 -5.74 
-1.81 0.285191 -5.74 
-6.16 0.013985 -5.74 
0.82 1.765406 -5.74 
-2.95 0.129408 -5.74 
-2.76 0.147624 -5.74 
-5.74 0.018711 -5.74 
-14.31 4.92E-05 -5.74 
-0.86 0.550953 -5.74 
12 4096 -5.74 
-0.33 0.795536 -5.74 
-2.05 0.241484 -5.74 
6.72 105.4197 -5.74 
-3.67 0.078563 -5.74 
-2.62 0.162668 -5.74 
1. A method of up-regulating one or more genes in cultured 65 
human bone marrow mesenchymal stem cells, the method 
comprising: 
0.018711 64 
0.018711 4.86E-05 
0.018711 15.24221 
0.018711 0.747425 
0.018711 94.35323 
0.018711 6.916298 
0.018711 7.889862 
0.018711 
0.018711 0.002631 
0.018711 29.446 
0.018711 218913.3 
0.018711 42.51795 
0.018711 12.90627 
0.018711 5634.219 
0.018711 4.198867 
0.018711 8.693879 
2. The method of claim 1, wherein the tail-regenerating 
lizard is a species of the family Polychrotidae. 
3. The method of claim 1, wherein the human bone marrow 
mesenchymal stem cells are cultured human bone marrow 
mesenchymal stem cells. 
US 8,105,832 Bl 
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4. A method of up-regulating one or more genes in human 
bone marrow mesenchymal stem cells, the method compris-
ing: 
co-culturing human bone marrow mesenchymal stem cells 
with a nutrient medium comprising cells from a tail 
section of an Anoles lizard; 
8 
wherein the up-regulated genes comprise a member from 
the group selected from Oct4, Sox2, TERT, TERP, and 
combinations thereof. 
* * * * * 
